CODEXIS, INC.

Codexis, Inc. reported a significant improvement in its financial performance for the first quarter of 2026, with total revenues more than doubling to $15.2 million, driven by strong growth in research and development revenue. The company also substantially reduced its net loss by 58% to $8.7 million compared to the prior year. Total cash, cash equivalents, and short-term investments increased to $65.1 million.

Codexis, Inc. announced its first quarter 2026 financial results, reporting total revenues of $15.2 million, a significant increase from $7.5 million in Q1 2025. The net loss improved substantially to $8.7 million, or $0.10 per share, compared to a net loss of $20.7 million, or $0.25 per share, in the prior year. The company also highlighted key business achievements, including ISO 9001 certification and FDA approval for a supported pharma product, and reiterated its full-year 2026 revenue guidance of $72 million to $76 million, with cash expected to fund operations through the end of 2027.

Codexis, Inc. announced it will present new data on its ECO Synthesis Manufacturing Platform and provide an update on regulatory engagement for its enzymatic platform at TIDES USA, held May 11–14. The presentations will highlight advances in controlling phosphorothioate stereochemistry, improved ligation efficiency, process performance, and the sustainability advantages of siRNA manufacturing. Codexis will also host an expert panel discussion on stereochemistry in RNAi manufacturing.

CODEXIS, INC. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 17, 2026. Stockholders will vote on the election of three Class I director nominees, the ratification of KPMG LLP as the independent registered public accounting firm for 2026, and an advisory vote on named executive officer compensation. The Board of Directors unanimously recommends voting for all proposals.

Codexis, Inc. announced the resignation of Dennis Wolf from its Board of Directors, Audit Committee, and Compensation Committee, effective April 8, 2026. The company stated that his departure was not due to any disagreements. Additionally, on April 10, 2026, Esther Martinborough, Ph.D., resigned and was immediately re-elected as a Class III director to achieve an equal balance among the Board's classes. Dr. Martinborough also assumed the role of Chair of the Science & Technology Committee.